vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs